<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03627988</url>
  </required_header>
  <id_info>
    <org_study_id>18 SEIN 11</org_study_id>
    <nct_id>NCT03627988</nct_id>
  </id_info>
  <brief_title>Prospective, Multicentric Study Evaluating the Surgical Treatment by Mastectomy With Immediate Prosthetic Breast Reconstruction in Patients With Breast Cancer and Receiving Adjuvant Therapy by TomoTherapy +/-Chemotherapy.</brief_title>
  <acronym>MARTA</acronym>
  <official_title>Prospective, Multicentric Study Evaluating the Surgical Treatment by Mastectomy With Immediate Prosthetic Breast Reconstruction in Patients With Breast Cancer and Receiving Adjuvant Therapy by TomoTherapy +/-Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicentric, non-randomized phase II study evaluating the surgical treatment by&#xD;
      mastectomy with immediate prosthetic breast reconstruction in patients with breast cancer and&#xD;
      receiving adjuvant therapy by TomoTherapy +/-Chemotherapy.&#xD;
&#xD;
      Patients with non-inflammatory and non-metastatic invasive mammary carcinoma will be included&#xD;
      in this study.&#xD;
&#xD;
      The study procedure will be a surgical treatment by mastectomy with immediate prosthetic&#xD;
      breast reconstruction followed by an adjuvant therapy: TomoTherapy +/-Chemotherapy (radiation&#xD;
      therapy alone or preceded by chemotherapy).&#xD;
&#xD;
      The nature of the chemotherapy treatment will be decided according to the standards of each&#xD;
      center.&#xD;
&#xD;
      The patients will be followed for the study up to 36 months after the surgical procedure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2019</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients with successful mastectomy strategy by immediate reconstruction.</measure>
    <time_frame>12 months for each patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of the radiotherapy treatment plan (dosimetry).</measure>
    <time_frame>60 months for all patients</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival.</measure>
    <time_frame>36 months for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early complications assessed using the National Cancer Institute Common Toxicity Criteria for Adverse Effects (NCI-CTCAE) version 4.03.</measure>
    <time_frame>36 months for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late complications assessed using the National Cancer Institute Common Toxicity Criteria for Adverse Effects (NCI-CTCAE) version 4.03.</measure>
    <time_frame>36 months for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessed using the questionnaire called &quot;Breast-Q&quot;.</measure>
    <time_frame>36 months for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic outcome of treated breast assessed using a questionnaire with a Likert scale.</measure>
    <time_frame>36 months for each patient</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Breast Cancer Invasive</condition>
  <arm_group>
    <arm_group_label>Patients with breast cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patients with invasive breast cancer will receive:</intervention_name>
    <description>Total mastectomy with Immediate prosthetic breast reconstruction&#xD;
Adjuvant therapy by TomoTherapy (radiation therapy alone or preceded by chemotherapy).</description>
    <arm_group_label>Patients with breast cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. Patient with a non-inflammatory and non-metastatic invasive mammary carcinoma.&#xD;
&#xD;
          3. Indication of mastectomy and immediate prosthetic breast reconstruction.&#xD;
&#xD;
          4. Patient wishing to have an immediate mammary reconstruction with prosthesis.&#xD;
&#xD;
          5. Pre-operative indication of an adjuvant radiotherapy (+/- chemotherapy).&#xD;
&#xD;
          6. OMS ≤ 2.&#xD;
&#xD;
          7. Patient affiliated to a Social Health Insurance in France.&#xD;
&#xD;
          8. Patient must provide written informed consent prior to any study specific procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Metastatic breast cancer.&#xD;
&#xD;
          2. Bilateral breast cancer.&#xD;
&#xD;
          3. Inflammatory breast cancer (T4d).&#xD;
&#xD;
          4. History of breast cancer within 5 years.&#xD;
&#xD;
          5. Previous neoadjuvant treatment for the ongoing disease.&#xD;
&#xD;
          6. Pregnant or breastfeeding women.&#xD;
&#xD;
          7. Any psychological, familial, geographical or sociological condition which does not&#xD;
             allow to respect the medical follow-up and/or compliance to study procedure.&#xD;
&#xD;
          8. Patient protected by law.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carole MASSABEAU, MD</last_name>
    <phone>05 31 15 54 09</phone>
    <email>massabeau.carole@iuct-oncopole.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène CHARITANSKY</last_name>
      <phone>05 56 33 78 57</phone>
      <email>h.charitansky@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire Du Cancer de Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole MASSABEAU, MD</last_name>
      <phone>05 31 15 54 09</phone>
      <email>massabeau.carole@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 2, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer Invasive</keyword>
  <keyword>TomoTherapy</keyword>
  <keyword>Immediate prosthetic breast reconstruction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

